Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

61.37 USD -1.17 (-1.87%)
Streaming Delayed Price Updated: 3:38 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 582,221
Open 63.00
Bid (Size) 61.35 (2)
Ask (Size) 61.39 (1)
Prev. Close 62.54
Today's Range 60.14 - 63.00
52wk Range 39.32 - 63.49
Shares Outstanding 125,520,380
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
From GlobeNewswire News Releases
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider... 
From PR Newswire

Performance

YTD
+8.08%
+8.08%
1 Month
+10.90%
+10.90%
3 Month
+32.38%
+32.38%
6 Month
+1.15%
+1.15%
1 Year
+2.25%
+2.25%

More News

Read More
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
From PR Newswire
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
From PR Newswire
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
From PR Newswire
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
From PR Newswire
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
From PR Newswire
Ionis to hold virtual investor day event
From PR Newswire
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
From PR Newswire
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
From PR Newswire
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.